Adults 18 to 55, any sex, with Malaria. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Crude Adequate Clinical and Parasitological Response (ACPR) for P. VivaxPrimary· On Day 14 post-dose
The absence of parasitaemia (thick smear) on Day 14, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure. Parasitaemia was defined as a P. vivax asexual forms count \>0
Group
Value
95% CI
Cohort 1A - P. Vivax Malaria
8
Adverse events — posted to ClinicalTrials.gov
Time frame: From IMP administration (Day 0) to End of Study (Day 35).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The present proof-of-concept Phase IIa study aims to confirm, in patients, the observed activity of MMV390048 against P. falciparum in pre-clinical models and the human Induced Blood-Stage Malaria (IBSM) challenge model, and to determine the activity against P. vivax malaria in patients, both over 14 and 28 days. Additional aims are to characterise the safety of MMV390048 in patients. Patient safety will be monitored for up to 35 days post-dose including pharmacokinetic assessments. The study will investigate descending single doses of MMV390048 in response to results obtained in the first cohort/dose in each malaria sub-type. The results of this trial will identify active, well-tolerated doses for investigation in combination with a partner drug within a Phase IIb clinical trial.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
· recruiting
NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
· Phase 2
· recruiting
NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI
· Phase 1
· active not recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants
· Phase 1
· recruiting
NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha
· Phase 1
· recruiting
Other Medicines for Malaria Venture trials
Trials by the same sponsor.
NCT07011511 — Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combinati
· Phase 1
· recruiting
NCT06558643 — Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participant
· Phase 1
· completed
NCT05361486 — Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
· completed
NCT05930782 — Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.
· Phase 1
· completed
NCT05979207 — Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medicines for Malaria Venture
Last refreshed: 9 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02880241.